Aclarion provides corporate update highlighting market expansion as clarity trial advances toward key data catalyst

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across u.s., u.k., and e.u. markets clarity pivotal trial progressing on schedule and early 3-month readouts expected q2 2026 as ai-driven disc pain biomarker validation continues webcast scheduled for october 20 th at 12:00 pm pt at the ld micro main event broomfield, colo.
ACON Ratings Summary
ACON Quant Ranking